Pfizer Inc.
$27.40-$0.14 (-0.5%)
Last close · Data as of Nov 20, 2026
- Market cap
- $146.4B
- P/E
- 18.8x
- EV / EBITDA
- 12.5x
- Revenue
- $62.6B
- Net margin
- 12.4%
- ROCE
- 9.2%
Price chart
Technical chartScreen technicals →+12.3% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -9.0%
- 3M
- -1.4%
- 6M
- +6.2%
- 1Y
- +12.3%
- 5Y
- -46.1%
52-week range
Day change -$0.14 (-0.5%) from $27.54 to $27.40 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in PFE, bought on each weekday since 2021.
News & filings
What Pfizer filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernNet profit fell 37.2% a year over three years.
Strengths (1)
- Operating margin of 25.2% against a peer median of 19.6%.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
Read moreShow less
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
- Sector
- Healthcare
- Shares outstanding
- 5.67B
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $146.4B
- P/E
- 18.8x
- P/B
- 1.7x
- EV / EBITDA
- 12.5x
- EV / Sales
- 3.3x
- P/S
- 2.3x
- 52-week high
- $30.79
- 52-week low
- $23.67
Profitability
- Operating margin
- 25.2%
- Net margin
- 12.4%
- EBITDA margin
- 26.8%
- ROE
- 9.0%
- ROCE
- 9.2%
- ROA
- 3.7%
- Asset turnover
- 0.30
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $62.6B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -1.6%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -14.8%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -3.2%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $9.1B
Solvency
- Current ratio
- 1.16
- Debt / Equity
- 0.74
- Debt / Assets
- 0.31
- CFO / Net profit
- 1.51
- Cash / Market cap
- 0.8%
Where the revenue went
Of every $100 of FY2025 revenue, $12 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $16.1B |
| Revenue | Gross profit | $46.5B |
| Gross profit | Research and development | $12.1B |
| Gross profit | Selling, general and administrative | $13.8B |
| Gross profit | Other operating expenses | $4.9B |
| Gross profit | Operating income | $15.8B |
| Operating income | Pretax income | $7.5B |
| Operating income | Interest and other expense | $8.3B |
| Pretax income | Net income | $7.5B |
| Tax benefit and other | Net income | $251.0M |
Revenue and net profit
Revenue fell 1.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $101.2B | $31.4B |
| FY2023 | $59.6B | $2.1B |
| FY2024 | $63.6B | $8.0B |
| FY2025 | $62.6B | $7.8B |
Cash flows
FY2025: $11.7B from operations, $9.1B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $29.3B | $26.0B |
| FY2023 | $8.7B | $4.8B |
| FY2024 | $12.7B | $9.8B |
| FY2025 | $11.7B | $9.1B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $62.6B-1.6%1Y
- EBITDA
- $16.8B-7.4%1Y
- Net profit
- $7.8B-3.2%1Y
- Cash from operations
- $11.7B-8.2%1Y
- Free cash flow
- $9.1B-7.7%1Y
- Revenue CAGR, 3Y
- -14.8%
- Net profit CAGR, 3Y
- -37.2%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $62.6B | $16.8B | $7.8B | $9.1B | 9.0% | -1.6% | -3.2% |
Monthly returns
Month-by-month returns of PFE across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $208.2B |
| Current assets | $42.9B |
| Non-current assets | $165.3B |
| Liabilities | $121.4B |
| Current liabilities | $37.0B |
| Non-current liabilities | $84.4B |
| Equity | $86.8B |
| Paid-in capital | $94.5B |
| Retained earnings | $114.6B |
| Treasury stock | $115.0B |
| Minority interest | $299.0M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; PFE highlighted.
P/E against peers
PFE trades at 18.8x earnings against a peer median of 31.1x (a 40% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Pfizer Inc.PFEthis companyP/E ↓ discount | $146.4B | 18.8x | 1.7x | 9.0% | 12.5x |
| Thermo Fisher Scientific Inc.TMO | $179.1B | 26.7x | 3.4x | 12.6% | 18.1x |
| Gilead Sciences, Inc.GILD | $160.4B | 18.8x | 7.1x | 37.5% | 12.9x |
| Abbott LaboratoriesABT | $158.1B | 24.2x | 3.0x | 12.5% | 13.5x |
| Intuitive Surgical, Inc.ISRG | $148.3B | 51.9x | 8.3x | 16.0% | 39.3x |
| Danaher CorporationDHR | $132.1B | 36.6x | 2.5x | 6.9% | 21.2x |
| CVS Health CorporationCVS | $121.0B | 68.4x | 1.6x | 2.4% | 19.5x |
| Bristol-Myers Squibb CompanyBMY | $115.6B | 16.4x | 6.3x | 38.2% | 10.0x |
| Stryker CorporationSYK | $115.5B | 35.6x | 5.2x | 14.5% | 20.2x |
| Peer median | — | 31.1x | 4.3x | 13.5% | 18.8x |
Year-to-date ROI
PFE since 1 January, against earlier years.
Historical volatility
PFE's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 36.7% |
| FY2023 | 7.1% |
| FY2024 | 23.3% |
| FY2025 | 25.2% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $62.6B |
| Cost of revenueCost Of Revenue | $16.1B |
| Gross profitGross Profit | $46.5B |
| Operating expensesOperating Expense | $30.7B |
| Research and developmentResearch And Development | $12.1B |
| Selling, general and administrativeSelling General And Administration | $13.8B |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $4.9B |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $4.9B |
| Amortization | $4.9B |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $4.9B |
| Total expensesTotal Expenses | $46.8B |
| Operating incomeOperating Income | $15.8B |
| Interest and other | |
| Pretax incomePretax Income | $7.5B |
| TaxTax Provision | -$266.0M |
| Net incomeNet Income | $7.8B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $208.2B |
| Current assetsCurrent Assets | $42.9B |
| Non-current assetsTotal Non Current Assets | $165.3B |
| LiabilitiesTotal Liabilities Net Minority Interest | $121.4B |
| Current liabilitiesCurrent Liabilities | $37.0B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $84.4B |
| EquityTotal Equity Gross Minority Interest | $86.8B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $11.7B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $11.7B |
| Net income, continuing operationsNet Income From Continuing Operations | $7.8B |
| Depreciation and amortisationDepreciation And Amortization | $6.6B |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $6.6B |
| Stock-based compensationStock Based Compensation | $799.0M |
| Deferred taxDeferred Tax | -$2.1B |
| Deferred income taxDeferred Income Tax | -$2.1B |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | — |
| Asset impairmentAsset Impairment Charge | $5.3B |
| Change in working capitalChange In Working Capital | -$5.4B |
| Other non-cash itemsOther Non Cash Items | -$1.3B |
| Cash from discontinued operating activitiesCash From Discontinued Operating Activities | — |
| Investing cash flowInvesting Cash Flow | -$1.4B |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$1.4B |
| Capital expenditureCapital Expenditure | -$2.6B |
| Purchase of PP&EPurchase Of PPE | -$2.6B |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$2.6B |
| AcquisitionsPurchase Of Business | -$6.9B |
| DisposalsSale Of Business | $6.3B |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$616.0M |
| Purchase of investmentsPurchase Of Investment | -$17.3B |
| Sale of investmentsSale Of Investment | $19.1B |
| Net investment purchases and salesNet Investment Purchase And Sale | $1.7B |
| Dividends received (investing)Dividends Received Cfi | — |
| Other investing changesNet Other Investing Changes | $165.0M |
| Cash from discontinued investing activitiesCash From Discontinued Investing Activities | — |
| Financing cash flowFinancing Cash Flow | -$10.3B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$10.3B |
| Debt issuedIssuance Of Debt | $9.7B |
| Debt repaidRepayment Of Debt | -$9.8B |
| Net debt issuedNet Issuance Payments Of Debt | -$74.0M |
| Short-term debt issuedShort Term Debt Issuance | $0.00 |
| Short-term debt repaidShort Term Debt Payments | -$3.0B |
| Net short-term debt issuedNet Short Term Debt Issuance | -$3.0B |
| Long-term debt issuedLong Term Debt Issuance | $9.7B |
| Long-term debt repaidLong Term Debt Payments | -$6.8B |
| Net long-term debt issuedNet Long Term Debt Issuance | $2.9B |
| Net common stock issuedNet Common Stock Issuance | — |
| Common stock repurchasedCommon Stock Payments | — |
| Share buybacksRepurchase Of Capital Stock | — |
| Dividends paidCash Dividends Paid | -$9.8B |
| Common dividends paidCommon Stock Dividend Paid | -$9.8B |
| Other financing chargesNet Other Financing Charges | -$459.0M |
| Cash from discontinued financing activitiesCash From Discontinued Financing Activities | — |
| Change in cashChanges In Cash | $49.0M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 4,100.0% |
| Cash at the start of the yearBeginning Cash Position | $1.1B |
| Cash at the end of the yearEnd Cash Position | $1.2B |
| Free cash flowFree Cash Flow | $9.1B |
| Supplemental |
Learn while you research
Academy chapters picked for Pfizer Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read